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A Randomized Clinical Trial
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Hanne Hedegaard Villesen, MSc, PhD; Christian Ljørring, MSc; Bente Riis, MSc, PhD; Frederic de Blay, MD
IMPORTANCE The house dust mite (HDM) sublingual allergen immunotherapy (SLIT) tablet is
a potential novel treatment option for HDM allergy–related asthma.
OBJECTIVES To evaluate the efficacy and adverse events of the HDM SLIT tablet vs placebo
for asthma exacerbations during an inhaled corticosteroid (ICS) reduction period.
DESIGN, SETTINGS, AND PARTICIPANTS Double-blind, randomized, placebo-controlled trial
conducted between August 2011 and April 2013 in 109 European trial sites. The trial included
834 adults with HDM allergy–related asthma not well controlled by ICS or combination
products, and with HDM allergy–related rhinitis. Key exclusion criteria were FEV1 less than
70% of predicted value or hospitalization due to asthmawithin 3months before
randomization. Efficacy was assessed during the last 6months of the trial when ICS was
reduced by 50% for 3 months and then completely withdrawn for 3 months.
INTERVENTIONS 1:1:1 randomization to once-daily treatment with placebo (n = 277) or HDM
SLIT tablet (dosage groups: 6 SQ-HDM [n = 275] or 12 SQ-HDM [n = 282]) in addition to ICS
and the short-acting β2-agonist salbutamol.
MAIN OUTCOMES ANDMEASURES Primary outcomewas time to first moderate or severe
asthma exacerbation during the ICS reduction period. Secondary outcomes were
deterioration in asthma symptoms, change in allergen-specific immunoglobulin G4 (IgG4),
change in asthma control or asthma quality-of-life questionnaires, and adverse events.
RESULTS Among834 randomizedpatients (meanage, 33 years [range, 17-83];women,48%),
693completed the study. The6SQ-HDMand 12SQ-HDMdosesboth significantly reduced the
risk of amoderateor severe asthmaexacerbation comparedwithplacebo (hazard ratio [HR]:0.72
[95%CI,0.52-0.99] for the6SQ-HDMgroup,P = .045, and0.69 [95%CI,0.50-0.96] for the 12
SQ-HDMgroup,P = .03). The absolute risk differencesbasedon theobserveddata (full analysis
set) in the active groups vs theplacebogroupwere0.09 (95%CI,0.01-0.15) for the6SQ-HDM
groupand0.10 (95%CI,0.02-0.16) for the 12 SQ-HDMgroup. Therewasno significant difference
between the2active groups. Comparedwithplacebo, therewas a reduced risk of anexacerba-
tionwithdeterioration in asthma symptoms (HR,0.72 [95%CI,0.49-1.02] for the6SQ-HDM
group,P = .11, and0.64 [95%CI,0.42-0.96] for the 12 SQ-HDMgroup,P = .03) anda significant
increase in allergen-specific IgG4.However, therewasno significant difference for change in
asthmacontrol questionnaire or asthmaquality-of-life questionnaire for either dose. Therewere
no reports of severe systemic allergic reactions. Themost frequent adverse eventsweremild to
moderateoral pruritus (13% for the6SQ-HDMgroup, 20%for the 12 SQ-HDMgroup, and3%for
theplacebogroup),mouthedema, and throat irritation.
CONCLUSIONS AND RELEVANCE Among adults with HDM allergy–related asthma not well
controlled by ICS, the addition of HDM SLIT to maintenancemedications improved time to
first moderate or severe asthma exacerbation during ICS reduction, with an estimated
absolute reduction at 6months of 9 to 10 percentage points; the reduction was primarily due
to an effect onmoderate exacerbations. Treatment-related adverse events were common at
both active doses. Further studies are needed to assess long-term efficacy and safety.
TRIAL REGISTRATION clinicaltrialsregister.eu Identifier: 2010-018621-19.
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B ronchial asthma is a seriousglobalhealthproblemwithincreasing prevalence inmany countries.1 House dustmite (HDM) sensitization is present inup to 50%ofpa-
tients with asthma,2 and exposure to HDM allergen has been
related to asthma severity.3
Persistent symptoms are common in many patients with
HDMallergic disease.4 Treatment options include inhaled cor-
ticosteroids (ICS) and long-acting β-agonists, but up to 30%of
patients remain symptomatic, uncontrolled, or both despite
treatment.5 Uncontrolled
asthma is identified as a
major risk factor for fu-
ture exacerbations and
poorer clinical outcomes.6
Allergen immuno-
therapy is the only treat-
ment option for allergic
disease with evidence of
a disease-modifying effect7 and thus a potential for sus-
tained benefits when therapy is terminated.
Allergen immunotherapy has been shown to be effective
in the treatment of allergic rhinitis due to airborne allergens,
including HDM allergen.8,9 Allergen immunotherapy im-
proves symptoms and reduces medication scores both dur-
ing treatment and following treatment cessation7,10 and has
been shown to prevent the development of asthma.11
Previously, the HDM sublingual allergen immuno-
therapy (SLIT) tablet hasproven tobeeffective in reducing the
requirement for ICS12,13 and in reducing allergic rhinitis symp-
tomsandneed forpharmacotherapy9,14,15 amongpatientswith
HDM respiratory allergic disease. However, to our knowl-
edge, the effect on risk of asthma exacerbations has not been
addressed previously.
This trial investigated the efficacy of theHDMSLIT tablet
amongparticipantswithHDMallergy–relatedasthma,notwell
controlled by ICS, andwith HDM allergy–related rhinitis. The
primary objective of the trial was to evaluate the efficacy of
theHDMSLIT tablet in2differentdoses (6SQ-HDMand 12SQ-
HDM)vsplacebo,measuredby reducing the risk for anasthma
exacerbation during a 6-month ICS reduction period.
Methods
The trial protocol (Supplement 1) and amendments were ap-
provedby the relevant ethics committees and institutional re-
view boards. The trial was a randomized, double-blind, par-
allel group, placebo-controlled trial, designed and conducted
inaccordancewith theprinciplesof theDeclarationofHelsinki
(adopted in 1964, and its amendments and subsequent
clarifications16) and in compliancewith the InternationalCon-
ference on Harmonisation of Technical Requirements for the
RegistrationofPharmaceuticals forHumanUse’s (ICH’s)Good
Clinical Practice guidelines.17 Written informed consent was
obtained from all participants.
The HDM SLIT tablet contains extract from 2 species
of cultivated HDM (Dermatophagoides pteronyssinus and
Dermatophagoides farinae), produced in a standardized pro-
cess with a 1:1:1:1 ratio of the major allergens (Group 1 aller-
gens of D farinae and D pteronyssinus and Group 2 allergens
of D farinae and D pteronyssinus), and formulated as a rapidly
dissolving oral lyophilisate for sublingual administration
(ALK). The biological activity of the HDM SLIT tablet is
related to the activity of the allergens and is expressed in the
unit SQ-HDM. The placebo and active products were similar
in appearance, smell, and taste. One tablet per day was to be
placed under the tongue, preferably in the morning. Eating
and drinking was not allowed for 5 minutes. The maximum
duration of treatment with the SLIT tablet was 18 months.
Randomizationwasperformed inblocks of 6 by the spon-
sor using the SAS system for Windows (SAS Institute), ver-
sion 9.3, which generates random assignment of treatment
groups to randomization numbers. Further details are pro-
vided in Supplement 2.
The trial was conducted at 109 sites in 13 European
countries from August 11, 2011, through April 24, 2013. The
participants were randomized (1:1:1) to receive placebo,
the 6 SQ-HDM tablets, or the 12 SQ-HDM tablets, as add-on
therapy to ICS and short-acting β2-agonists (SABA). Eligible
patients were adults with a positive result for the HDM-
specific serum immunoglobulin E (IgE) and skin prick test; a
clinical history of more than 1 year of allergic asthma and
allergic rhinitis with HDM being considered clinically as a
major trigger, not well controlled by ICS (equivalent to budes-
onide, 400-1200 μg) at inclusion; and a forced expiratory
volume in the first second of expiration (FEV1) at randomiza-
tion of 70% or more of predicted value. The Asthma Control
Questionnaire (ACQ) score18 required for randomization had
to be from 1 through 1.5 (score range, 0-6; values below
1 = controlled asthma, values above 1.5 = uncontrolled
asthma). Hospitalization due to an asthma exacerbation
within 3 months prior to randomization was an exclusion cri-
terion. Participants could have multiple sensitizations but
were not allowed to have a relevant clinical history of peren-
nial allergic asthma or rhinitis caused by other allergens. As
part of the baseline data collection, site staff collected data
on demographic characteristics, including race and ethnicity
ascertained by multiple choices (Caucasian, Asian, African,
Hispanic, or other [with room for specification]). Information
on race and ethnicity was collected because it was recom-
mended by the US Food and Drug Administration and ICH
guidance (E5[R1], Ethnic Factors in the Acceptability of For-
eign Clinical Data) that sponsors collect ethnicity data in
clinical trials to assist in assessing the relevance of foreign
study population data to US populations and be able to
bridge data to new regions. Further details are listed in
Supplement 2.
The trial design is shown in eFigure 1 in Supplement 2.
Period 1 included screening and switching of all participants
from their regular ICS asthma controller to budesonide and
SABA. Diary recordings of the last 2 weeks of period 1 served
as participant's individual baseline. From randomization and
throughout period 2, the participants received their assigned
intervention in addition to ICS and SABA. The duration of the
period varied from 7 to 12 months depending on the time of
inclusion because period 2 had a fixed stop date in October.
HDM house dust mite
FAS full analysis set
ICS inhaled corticosteroid(s)
MID minimal important difference
SABA short-acting β2-agonist
SLIT sublingual allergen
immunotherapy
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During the last approximately 4 weeks of period 2, the par-
ticipant started filling in the electronic diary and recorded
asthma symptoms, medication use, and lung function twice
daily. Efficacy was primarily assessed during the ICS reduc-
tion and withdrawal period (period 3) that began in October
2012 and covered the last 6 months of the treatment period.
Daily ICS use was reduced to 50% for 3 months and subse-
quently withdrawn completely for participants who did not
experience an asthma exacerbation. The primary end point,
time to first moderate or severe asthma exacerbation (de-
fined below), was measured from the start of period 3 until
the time of the first asthma exacerbation.
An asthma exacerbation was defined according to the
American Thoracic Society and European Respiratory Soci-
ety (ATS/ERS) recommendation19,20; and in practice de-
scribed by 1 or more of the following criteria for moderate or
severe asthma exacerbation leading to a change in treatment.
Criteria for a moderate asthma exacerbation included
(1) nocturnal awakening(s) due to asthma requiring SABA use
for at least 2 consecutive nights or an increase of at least 0.75
points in daily symptom score from baseline value on at least
2 consecutive days; (2) an increase from baseline in SABA use
on at least 2 consecutive days (a minimum increase of 4 puffs
per day); (3) a 20% or more decrease in peak expiratory flow
from baseline on at least 2 consecutive mornings or evenings
or a 20% or more decrease in FEV1 from baseline; and (4) a
visit to the emergency department or an unscheduled visit
to the trial site for asthma treatment not requiring systemic
corticosteroids.
Criteria for a severe asthmaexacerbation included (1) a re-
quirement for systemic corticosteroids for the treatment of
asthmasymptoms for at least 3days; and (2) anemergencyde-
partment visit due to asthma requiring systemic corticoste-
roids,orahospitalization formore than12hoursduetoasthma.
Baseline valueswere defined as themean values for each
individual participant during the last 14 days of the screening
period.
Key secondary end points included time to first asthma
exacerbation from the start of the ICS reduction and with-
drawal period (period 3) with deterioration in asthma symp-
toms and nocturnal awakenings; changes from baseline in
HDM-specific immunoglobulin G4 (IgG4); and the propor-
tion of participants with a minimal important difference
(MID; defined as change >0.5) in ACQ or standardized
Asthma Quality of Life Questionnaire (AQLQ[S]) score with-
out an increased dose of ICS, or with no MID in ACQ or
AQLQ(S) score despite lower ICS usage at the end of trial
(third and fourth key secondary end points). Of the 17 pre-
specified exploratory end points, this article reports the fol-
lowing 3 that are related to the primary end point: (1) time
to first asthma exacerbation from the start of period 3 with
an increased use of SABA; (2) the time to the first asthma
exacerbation from the start of period 3 with deterioration in
lung function; and (3) time to the first severe asthma exac-
erbation from the start of period 3.
Safety assessments included adverse events reporting,
findings on physical examinations, vital signs, lung function
measurements (peak expiratory flow and FEV1), and clinical
safety laboratory assessments (details listed inSupplement2).
Adverse eventswere codedusingMedDRA (ICH), version 15.0.
Statistics
The principal statistical software used was SAS (SAS Insti-
tute), version 9.3. Details of the sample size calculation and
statistical methodology are provided in Supplement 2 and in
the statistical analysis plan (Supplement 1).
In brief, the power calculation was based on the assump-
tion that about 65% of participants in the placebo group
would experience an asthma exacerbation. The assumption
was based on a small ICS withdrawal trial, in which loss of
asthma control developed in 8 of 12 placebo-treated patients
over the 10-week period of ICS withdrawal.21 A reduction in
the rate of first asthma exacerbation of approximately 30%,
corresponding to a hazard ratio (HR) of 0.70, was considered
clinically relevant. Accordingly, it was estimated that 266
participants per treatment group would provide at least an
80% power to detect a difference between HDM SLIT tablet
and placebo in the time to first asthma exacerbation corre-
sponding to an HR of 0.70 at the 5% significance level (in-
cluding an expected dropout of about 10%).
The full analysis set (FAS) included all randomized par-
ticipants in accordance with the ICH intention-to-treat prin-
ciple. The primary analysis was based on the FAS with mul-
tiple imputations (FAS-MI) ofmissing data. All other analyses
were based on the FAS.
The primary efficacy analysis of time to first moderate or
severe asthma exacerbation was performed with a Cox pro-
portional hazards regression analysis stratified for country.
Multiplicity was controlled by a prespecified hypothesis test
strategy. The first hypothesis to be testedwas the hypothesis
that all 3 groupswere equal, controlled by Fisher least signifi-
cant differenceprocedure.22 This procedurepreserves the ex-
perimentwise type I error rate at the nominal level of signifi-
cance in case of 3 treatment groups. Time to the first asthma
exacerbation by individual criteria was analyzed similarly to
the primary efficacy end point. Log-transformed IgG4 at the
endof the trialwas analyzedwitha linearmixed-effectmodel.
Analyses of the odds for improvement (defined as a0.5 points
change from baseline23,24) in ACQ or AQLQ(S) score con-
trolled for ICSwas performedwith a logistic regression analy-
sis. The 4 key secondary hypotheseswere tested in hierarchi-
cal order, first for thecomparisonof the 12SQ-HDMgroupwith
the placebo group and then for the 6 SQ-HDM groupwith the
placebo group. The procedure continued if a hypothesis was
rejected (P < .05). Other secondary analyseswere considered
supportive in nature andwere not controlled formultiplicity.
Safetydatawere reportedbydescriptive statistics only.All
analyses were 2-sided and tested at a 5% significance level.
Results
A total of 834 participants were randomized to receive the 6
SQ-HDMtablets (n = 275), 12 SQ-HDMtablets (n = 282) or pla-
cebo (n = 277). Participant characteristics through the entire
trial are summarized inFigure 1. Across treatmentsgroups, the
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number of dropouts were comparable (6 SQ-HDM group, 72
participants [26%]; 12 SQ-HDM group, 77 participants [27%];
placebo group, 68 participants [25%]). The main reasons for
trial discontinuations were asthma exacerbations during the
ICS reductionperiod (ie, aftermeeting theprimary endpoint),
adverseeventsandwithdrawalsof consent.Thenumberofdis-
continuations due to adverse events was numerically higher
in the 12 SQ-HDM group (n = 25) whereas the number of dis-
continuations following an asthma exacerbation was higher
in the placebo group (n = 24) (Figure 1).
Additionalcharacteristicsanddisease-specificbaselineval-
ues are listed in Table 1. There were no major differences be-
tween the 3 groups. The overall mean duration of allergic
asthma was 13 years (SD, 11 years). Approximately one-third
of the populationwasmonosensitized toHDM,whereas one-
thirdhad3ormoreadditionalallergensensitizations.Themean
daily ICS use at randomizationwas 588μg of budesonide (SD,
252 μg), and this level remained stable throughout themain-
tenance phase (period 2) of the trial, with no difference in ICS
use between groups at the start of the efficacy assessment
Figure 1. Participant Disposition Throughout the Trial
428 Excluded
364 Did not meet inclusion criteriaa
45 Declined to participate
19 Other reason
175 Specific lgE < class 2
79 Did not have documented
reversible airway obstruction
51 ACQ score outside required range
42 Negative SPT
34 FEV1 <70% predicted
277 Randomized to receive placebo
277 Received placebo as
randomized
275 Randomized to receive
6 SQ-HDM tablet
275 Received 6 SQ-HDM
tablet as randomized
282 Randomized to receive
12 SQ-HDM tablet
282 Received 12 SQ-HDM
tablet as randomized
257 Included in the full analysis set 237 Included in the full analysis set 248 Included in the full analysis set
257 Entered efficacy assessment period 237 Entered efficacy assessment period 248 Entered efficacy assessment period
237 Attended planned end-of-trial visit
or had an asthma exacerbation
fulfilling the primary end point c
229 Attended planned end-of-trial visit
or had an asthma exacerbation
fulfilling the primary end point c
227 Attended planned end-of-trial visit
or had an asthma exacerbation
fulfilling the primary end point c
834 Randomized
1262 Participants assessed for eligibility
20 Discontinuations during period 2 b
3 Adverse events
1 Lack of efficacy
2 Lost to follow-up
1 Nonadherent to protocol
4 Pregnancy
8 Withdrawal of consent
1 Other
38 Discontinuations during period 2 b
9 Adverse events
1 Lack of efficacy
3 Lost to follow-up
5 Nonadherent to protocol
1 Pregnancy
14 Withdrawal of consent
5 Other
34 Discontinuations during period 2 b
21 Adverse events
1 Lack of efficacy
1 Lost to follow-up
1 Nonadherent to protocol
1 Pregnancy
7 Withdrawal of consent
2 Other
48 Discontinuations during period 3 b
5 Adverse events
1 Lack of efficacy
3 Lost to follow-up
7 Nonadherent to protocol
2 Pregnancy
5 Withdrawal of consent
1 Other
24 Due to first asthma exacerbation
34 Discontinuations during period 3 b
3 Adverse events
3 Lost to follow-up
1 Nonadherent to protocol
2 Withdrawal of consent
3 Other
22 Due to first asthma exacerbation
43 Discontinuations during period 3 b
4 Adverse events
2 Lost to follow-up
6 Nonadherent to protocol
8 Withdrawal of consent
4 Other
19 Due to first asthma exacerbation
ACQ indicates Asthma Control Questionnaire; FEV1, forced expiratory volume in
the first second of expiration; ICS, inhaled corticosteroids; IgE, immunoglobulin
E; SPT, skin prick test. The biological activity of the house dust mite sublingual
allergen immunotherapy tablet is related to the activity of the allergens and is
expressed in the unit SQ-HDM.
a More than 1 criterion could apply to each individual.
b Period 2, in which participants received the intervention as an add-on to ICS,
lasted 7 to 12 months; period 3, in which participants began ICS
reduction/withdrawal, lasted 6months.
c The protocol defined that, following an asthma exacerbation, participants were
offered to continue in the trial at an adjusted ICS dose and provide data to
secondary end points. The participants discontinuing the trial following an
exacerbationwere considered to have completed the trial (26 participants in the
6 SQ-HDMgroup, 22 in the 12 SQ-HDMgroup, and 28 in the placebo group).
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Table 1. Participant Demographics and Asthma Characteristics at Baseline
Treatment Group
Placebo
(n = 277)
6 SQ-HDM Tablet
(n = 275)a
12 SQ-HDM Tablet
(n = 282)a
Overall
(N = 834)
Participant Demographics
Sex, No. (%)
Men 151 (55) 133 (48) 147 (52) 431 (52)
Women 126 (45) 142 (52) 135 (48) 403 (48)
Ethnic origin, No. (%)
Caucasian 273 (99) 272 (99) 277 (98) 822 (99)
Asian 1 (<1) 1 (<1) 2 (<1) 4 (<1)
African 1 (<1) 1 (<1) 2 (<1) 4 (<1)
Hispanic 2 (<1) 0 1 (<1) 3 (<1)
Other 0 1 (<1) 0 1 (<1)
Smoking history, No. (%)
Nonsmoker 214 (77) 198 (72) 214 (76) 626 (75)
Previous smoker 36 (13) 50 (18) 38 (13) 124 (15)
Smoker 27 (10) 27 (10) 30 (11) 84 (10)
Sensitization status, No. (%)b
Only HDM 102 (37) 90 (33) 91 (32) 283 (34)
1 other than HDM 44 (16) 51 (19) 45 (16) 140 (17)
2 others than HDM 41 (15) 37 (13) 48 (17) 126 (15)
≥3 others than HDM 90 (32) 97 (35) 98 (35) 285 (34)
Age, mean (SD), y 33.0 (12.2) 33.6 (11.3) 33.7 (11.6) 33.4 (11.7)
Median (range) 30 (18.0-83.0) 32 (18.0-75.0) 32 (17.0-74.0) 31 (17.0-83.0)
Weight, mean (SD), kg 76.3 (16.7) 76.5 (16.4) 75.9 (16.3) 76.2 (16.4)
Median (range) 76 (42.0-145.5) 76 (45.0-118.0) 74 (45.0-125.0) 75 (42.0-145.5)
Height, mean (SD), cm 172.8 (10.5) 171.2 (9.5) 171.6 (9.4) 171.9 (9.8)
Median (range) 173 (151.0-200.0) 171 (150.0-198.0) 172 (150.0-197.0) 172 (150.0-200.0)
BMI, mean (SD) 25.5 (5.0) 26.0 (4.8) 25.7 (4.7) 25.7 (4.8)
Median (range) 24.7 (16.4-54.0) 25.3 (17.0-40.2) 25.1 (17.4-44.0) 25.0 (16.4-54.0)
Participant Asthma Characteristics
Average morning PEF, mean (SD),
L/min
456 (132) 433 (124) 443 (125) 444 (127)
Median (range) 451 (171-827) 418 (104-758) 418 (179-805) 425 (104-827)
Average diurnal variability in PEF,
mean (SD), %
8.50 (4.70) 9.05 (5.94) 8.29 (5.19) 8.61 (5.30)
Median (range) 7.43 (2.04-32.80) 7.36 (2.07-40.28) 6.98 (0.90-29.65) 7.23 (0.90-40.28)
FEV1 at randomization, L
Mean (SD) 3.52 (0.89) 3.33 (0.79) 3.33 (0.82) 3.39 (0.84)
Median (range) 3.41 (1.62-6.35) 3.23 (1.81-5.92) 3.24 (1.67-5.57) 3.29 (1.62-6.35)
FEV1, % of predicted value, mean (SD) 94.34 (13.79) 92.32 (12.66) 91.39 (12.91) 92.67 (13.17)
Median (range) 92.8 (68.0-134.4) 90.6 (63.4-127.0) 90.9 (69.5-131.6) 91.1 (63.4-134.4)
ACQ at randomizationc 1.22 (0.18) 1.24 (0.17) 1.23 (0.17) 1.23 (0.17)
Median (range) 1.17 (0.86-2.00) 1.29 (0.86-1.71) 1.29 (0.71-1.57) 1.29 (0.71-2.00)
AQLQ(S) score at randomization,
mean (SD)
5.54 (0.78) 5.46 (0.88) 5.49 (0.78) 5.50 (0.81)
Median (range) 5.61 (2.19-6.97) 5.63 (1.22-6.84) 5.56 (2.44-6.88) 5.59 (1.22-6.97)
ICS at randomization, mean (SD),
μg of budesonide/d
580 (246) 582 (246) 602 (264) 588 (252)
Median (range) 400 (400-1200) 400 (200-1200) 400 (200-1200) 400 (200-1200)
Total asthma daytime symptom score,
mean (SD)d
2.63 (2.05) 2.73 (1.98) 2.58 (1.92) 2.64 (1.98)
Median (range) 2.14 (0.00-12.00) 2.46 (0.00-10.36) 2.31 (0.00-8.93) 2.31 (0.00-12.00)
Asthma nocturnal symptom score,
mean (SD)
0.61 (0.56) 0.64 (0.54) 0.57 (0.50) 0.61 (0.53)
Median (range) 0.46 (0.00-2.86) 0.57 (0.00-2.25) 0.50 (0.00-2.14) 0.50 (0.00-2.86)
(continued)
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period. Approximately 40% of the participants used 800 μg
to 1200 μg of budesonide per day at randomization. At ran-
domization,meanasthmacontrol score (asdeterminedbyACQ)
was 1.24 (0.17) for the 6 SQ-HDM group, 1.23 (0.17) for the 12
SQ-HDM group, and 1.22 (0.18) for the placebo group. A pre-
specified evaluationof theGlobal Initiative forAsthma (GINA)
asthma control level (according to an algorithm previously
described)25 showedthatoverall 72%ofparticipantshadpartly
controlled asthma and 28% of participants had uncontrolled
asthma at randomization. Themain reasons for being uncon-
trolled according toGINA criteriawere nocturnal awakenings
and activity limitations in combination with daytime symp-
toms, anFEV1below80%ofpredictedvalue, orneed for SABA
use. At the start of period 3 when ICS was reduced, the mean
participant ACQ score was 0.98 for the 6 SQ-HDM group, and
0.93 for the 12 SQ-HDMgroup, and 1.01 for the placebo group.
Compliance to treatment was 94% with no differences be-
tween groups.
The primary efficacy results for time to the first asthma
exacerbation are shown in Table 2. At the end of the 6-month
efficacy assessment period, 6 SQ-HDM and 12 SQ-HDM tab-
lets significantly reduced the risk of a moderate or severe
asthmaexacerbation comparedwithplacebo (HR for theFAS-
MI:0.72 [95%CI,0.52-0.99] for the6SQ-HDMgroup,P = .045,
and0.69 [95%CI,0.50-0.96] for the 12SQ-HDMgroup,P = .03;
Kaplan-Meier–estimatedabsolute risk for first exacerbation for
the FAS: 0.24 (n = 62) for the 6 SQ-HDM group, 0.24 (n = 59)
for the 12 SQ-HDM group, and 0.33 (n = 83) for the placebo
group; risk difference vs placebo: 0.09 [95%CI, 0.01-0.15] for
the 6 SQ-HDM group and 0.10 [95% CI, 0.02-0.16] for the 12
SQ-HDM group). However, there was no significant differ-
ence between the 2 active groups (HR, 0.96 [95% CI, 0.68-
1.37], P = .84).
The proportions of participants with a moderate or se-
vere asthma exacerbation for the FAS are shown in Figure 2.
There were no statistically significant interactions be-
tween treatment andanyprespecified subgroupvariable (sex,
allergen sensitization type, other indoor sensitizations, or age
group) (Supplement 2).
Theprespecifiedsecondaryanalysesof timeto first asthma
exacerbation for the individual criteria aredisplayed inTable2.
For the 12 SQ-HDMgroup, therewas a statistically significant
and clinically relevant reduction in the HR for a moderate
asthmaexacerbationwith deterioration in asthma symptoms
ornocturnal awakeningsof0.64 [0.42-0.96] (first key second-
ary end point), for a moderate asthma exacerbation with de-
terioration in lung functionof0.58 [0.36-0.93], and for amod-
erate asthma exacerbation with increased SABA use of 0.52
[0.29-0.94] (exploratoryendpoints). For the6SQ-HDMgroup,
only time to first asthma exacerbation with deterioration in
lung functionwas statistically significantlydifferent frompla-
cebo (HR, 0.60 [0.38-0.95]; P = .030) (Table 2). The explor-
atory analysis of time to first severe asthma exacerbation
showednostatistically significant reductions (HR:0.79 [0.40-
1.55] for the6SQ-HDMgroup,P = .49, and0.49 [0.23-1.08] for
the 12 SQ-HDM group, P = .08).
The HDM SLIT tablet groups experienced dose-
dependent increases in allergen-specific IgG4 (to D pteronys-
sinus and D farinae) (Table 2) (second key secondary out-
come). The between-groupdifferences for both active groups
vs placebo were statistically significant from week 4 and on-
wards (eFigure 2 in Supplement 2). At the end of trial, the be-
tween-groupdifference in log10-transformed IgG4 toDptero-
nyssinus for the 6 SQ-HDM group vs placebo groupwas 0.461
(0.417-0.505), P < .001, and 0.595 (0.546-0.643) for the
12 SQ-HDM group vs placebo, P < .001.
Table 1. Participant Demographics and Asthma Characteristics at Baseline (continued)
Treatment Group
Placebo
(n = 277)
6 SQ-HDM Tablet
(n = 275)a
12 SQ-HDM Tablet
(n = 282)a
Overall
(N = 834)
Nocturnal awakening requiring SABA
intake, mean (SD)e
0.12 (0.26) 0.12 (0.23) 0.11 (0.23) 0.12 (0.24)
Median (range) 0 (0.00-1.00) 0 (0.00-1.00) 0 (0.00-1.00) 0 (0.00-1.00)
24-h SABA intake, mean (SD),
No. of 200-μg puffs
1.30 (1.53) 1.42 (1.87) 1.23 (1.47) 1.32 (1.63)
Median (range) 0.82 (0.00-11.14) 0.85 (0.00-14.25) 0.67 (0.00-7.38) 0.77 (0.00-14.25)
IgG4, mean (SD), mgA/L
Dermatophagoides pteronyssinus 0.5 (0.5) 0.4 (0.4) 0.4 (0.6) 0.4 (0.5)
Median (range) 0.3 (0.0-3.4) 0.3 (0.0-3.3) 0.3 (0.0-6.4) 0.3 (0.0-6.4)
Dermatophagoides farinae 0.4 (0.5) 0.4 (0.3) 0.5 (0.9) 0.4 (0.6)
Median (range) 0.3 (0.0-3.7) 0.3 (0.0-2.7) 0.2 (0.0-9.8) 0.3 (0.0-9.8)
Abbreviations: ACQ, asthma control questionnaire; AQLQ(S), asthma
quality of life questionnaire (standardized); BMI, bodymass index (calculated as
weight in kilograms divided by height in meters squared); FEV1, forced
expiratory volume in the first second of expiration; ICS, inhaled corticosteroid;
IgG4, immunoglobulin G4; mgA/L, milligram antigen-specific antibodies per
liter; PEF, peak expiratory flow; SABA, short-acting β2-agonist.
a The biological activity of the house dust mite sublingual allergen
immunotherapy tablet is related to the activity of the allergens and is
expressed in the unit SQ-HDM.
bThemost common cosensitizations by skin prick test were cat (43% positive)
and grass (41% positive).
c Asthma nocturnal symptom score: range, 0 to 3; worst asthma symptom
(wheezing, coughing, shortness of breath, or chest tightness) during the night
on a 0 to 3 scale (0 indicated no symptoms, 3 indicated severe symptoms).
dAsthma daytime symptom score: range 0 to 12; sum of severity of each
asthma symptom (wheezing, coughing, shortness of breath and chest
tightness, and exercise induced symptoms) during the day on a 0 to 3 scale
(0 indicated no symptoms, 3 indicated severe symptoms).
e For each participant themean number of nocturnal awakenings with SABA
intake over the 14-day baseline period.
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Table 2. Overview of Primary, Key Secondary, and Exploratory End Point Efficacy Results for Each Treatment Group
End Point
Total
Participants
No. of Participants
With Event
Treatment Effect
HR (95% CI) P Value
Primary End Point
Time to first asthma exacerbation
from the start of period 3a
FAS-MIb
Placebo group 277 NAc Reference
6 SQ-HDM group 275 NAc 0.72 (0.52 to 0.99) .045
12 SQ-HDM group 282 NAc 0.69 (0.50 to 0.96) .03
FAS
Placebo group 257 83 (32) Reference
6 SQ-HDM group 237 62 (26) 0.69 (0.49 to 0.96)d .03
12 SQ-HDM group 248 59 (24) 0.66 (0.47 to 0.93)d .02
Key Secondary End Points
Time to first asthma exacerbation
with deterioration in asthma symptoms
or nocturnal awakenings
Placebo group 257 57 (22) Reference
6 SQ-HDM group 237 45 (19) 0.72 (0.49 to 1.07) .17
12 SQ-HDM group 248 39 (16) 0.64 (0.42 to 0.96) .03
Change from baseline to end of trial
in log10-transformed IgG4
Dermatophagoides pteronyssinus
Placebo group 235 Mean (SD):
−0.037 (0.014)
Reference
6 SQ-HDM group 217 Mean (SD):
0.425 (0.022)
MD (95% CI):
0.461 (0.417 to 0.505)
<.001
12 SQ-HDM group 226 Mean (SD):
0.558 (0.024)
MD (95% CI):
0.595 (0.546 to 0.643)
<.001
Dermatophagoides farinae
Placebo group 235 Mean (SD):
−0.054 (0.015)
Reference
6 SQ-HDM group 217 Mean (SD):
0.404 (0.022)
MD (95% CI):
0.458 (0.413 to 0.503)
<.001
12 SQ-HDM group 226 Mean (SD):
0.540 (0.026)
MD (95% CI):
0.595 (0.543 to 0.646)
<.001
Improvement in ACQ score controlled for ICSe,f
Placebo group 277 No. (estimate in %):
218 (78.88)
Reference
6 SQ-HDM group 275 No. (estimate in %):
221 (80.63)
OR (95% CI):
1.12 (0.73 to 1.70)
ND
12 SQ-HDM group 282 No. (estimate in %):
232 (83.02)
OR (95% CI):
1.31 (0.85 to 2.01)
.22
Improvement in AQLQ(S) score controlled for ICSe,f
Placebo group 277 No. (estimate in %):
233 (84.80)
Reference
6 SQ-HDM group 275 No. (estimate in %):
231 (84.98)
OR (95% CI):
1.01 (0.63 to 1.62)
ND
12 SQ-HDM group 282 No. (estimate in %):
236 (84.39)
OR (95% CI):
0.97 (0.61 to 1.53)
.89
Exploratory End Points
Time to first asthma exacerbation
with increased use of SABA
Placebo group 257 32 (12) Reference
6 SQ-HDM group 237 23 (10) 0.62 (0.36 to 1.07) .09
12 SQ-HDM group 248 18 (7) 0.52 (0.29 to 0.94) .03
Time to first asthma exacerbation
with deterioration in lung function
Placebo group 257 45 (18) Reference
6 SQ-HDM group 237 31 (13) 0.60 (0.38 to 0.95) .03
12 SQ-HDM group 248 30 (12) 0.58 (0.36 to 0.93) .02
(continued)
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The analyses of the odds for improvement in ACQ or
AQLQ(S) score without an increased dose of ICS (third and
fourth key secondary outcomes) showed no statistically sig-
nificantdifferencesbetweenactivetreatmentandplacebo(ACQ
scoreodds ratio [OR]: 1.12 [95%CI,0.73-1.70] for the6SQ-HDM
group vs placebo group and 1.31 [95%CI, 0.85-2.01] for the 12
SQ-HDMgroupvsplacebogroup;AQLQ(S) scoreOR: 1.01 [95%
CI, 0.63-1.62] for the 6 SQ-HDM group vs placebo group and
0.97 [95% CI, 0.61-1.53] for the 12 SQ-HDM group vs placebo
group) (Table 2).
Overall, 599participants (72%) reportedadverse events in
a dose-dependent manner with the majority of all adverse
eventsbeingmild (eTable2 inSupplement2).Therewasadose-
dependent change in the numbers of participants with treat-
ment-related adverse events (39% from the6 SQ-HDMgroup,
46% from the 12 SQ-HDM group, and 17% from the placebo
group). The 3 most frequently reported adverse events were
oralpruritus,mouthedema, and throat irritation (Table3). The
most commonadverse eventshadamedianonset timeonday
1 or 2 after start of the treatment. The median onset in min-
utes on day 1 was 1 to 2minutes. Themedian number of days
from start of the adverse event until the event no longer oc-
curred was 4.5 days for oral pruritus, 7 days for throat irrita-
tion, and23days formouthedema.Therewereno safety find-
ings of clinical concern in the subgroupwith asthmaclassified
as uncontrolled according to GINA.
No deaths occurred during the trial and there were no
anaphylactic reactions, severe systemic allergic reactions,
adverse events requiring epinephrine, or local allergic reac-
tions compromising the airways. Twenty-eight participants
reported 32 serious adverse events of which 5 were assessed
as possibly treatment-related (for placebo [2 participants]:
erosive esophagitis, hepatocellular injury; for 6 SQ-HDM tab-
let [2 participants]: arthralgia, laryngeal edema [moderate,
no airway obstruction or dyspnea]; and for 12 SQ-HDM tablet
[1 participant]: asthma [moderate, alternative etiology was
“recently viral infection”]). There were no clinically relevant
findings from clinical safety laboratory tests, physical exami-
nations or vital signs.
Discussion
HDMis themost commonallergenassociatedwithasthmaand
more than 40% of adult asthmatics are atopic with a positive
skinprick test result for theHDMallergens.26,27Althoughmany
Figure 2. Probability of Having the First Moderate or Severe Asthma
Exacerbation in the Full Analysis Set
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ICS indicates inhaled corticosteroid. The biological activity of the house dust
mite sublingual allergen immunotherapy tablet is related to the activity of the
allergens and is expressed in the unit SQ-HDM. At the end of the 6-month
efficacy assessment period, the 6 SQ-HDM and 12 SQ-HDM tablets significantly
reduced the risk of a moderate or severe asthma exacerbation compared with
placebo (hazard ratios: 0.69 [95% CI, 0.49-0.96] for the 6 SQ-HDM group,
P = .03, and 0.66 [95% CI, 0.47-0.93] for the 12 SQ-HDM group, P = .02;
absolute risk for first exacerbation: 24% for the 6 SQ-HDM group [n = 62], 24%
for the 12 SQ-HDM group [n = 59], 33% for the placebo group [n = 83]; risk
difference vs placebo: 9% [95% CI, 1%-15%] for the 6 SQ-HDM group and 10%
[95% CI, 2%-16%] for the 12 SQ-HDM group). There was no significant
difference between the 2 active groups (hazard ratio, 0.96 [95% CI, 0.68-1.37],
P = .84).
Table 2. Overview of Primary, Key Secondary, and Exploratory End Point Efficacy Results for Each Treatment Group (continued)
End Point
Total
Participants
No. of Participants
With Event
Treatment Effect
HR (95% CI) P Value
Time to first severe asthma exacerbation
Placebo group 257 18 (7) Reference
6 SQ-HDM group 237 17 (7) 0.79 (0.40 to 1.55) .49
12 SQ-HDM group 248 10 (4) 0.49 (0.23 to 1.08) .08
Abbreviations: ACQ, asthma control questionnaire; AQLQ(S), asthma quality of
life questionnaire; FAS-MI, full analysis set with multiple imputation of missing
data; HR, hazard ratio; MD, mean difference; NA, not applicable; ND, not done
as per the hierarchical testing plan; OR, odds ratio.
a Period 3 was the start of the ICS reduction/withdrawal period (global null
hypothesis [placebo = 6 SQ-HDM = 12 SQ-HDM; P = .047]).
b The number of participants with imputed data was 20 (7%) participants in
the placebo group, 38 (14%) in the 6 SQ-HDM group, and 34 (12%) in the
12 SQ-HDM group.
c In FAS-MI, the number of participants with first exacerbation is not applicable
due to the imputation, in which participants who discontinued the study
during period 2 were included as sampled from the placebo distribution of
time to first asthma exacerbation during period 3.
d The absolute risk differences compared with the placebo group were 0.09
(95% CI, 0.01-0.15) for the 6 SQ-HDM group and 0.10 (95% CI, 0.02-0.16) for
the 12 SQ-HDM group.
e Improvement in ACQ and AQLQ(S) score was defined as a change from
baseline of more than 0.5 (ie, the establishedminimal important
difference23,24). The odds ratio, 95% CI, and P value relate to the proportions
with improvement.
f Estimate in percentage is based on the linearmixed-effectmodel with treat-
ment group, baseline value as fixed effects and country as a randomeffect.
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patients with persistent asthma symptoms can be success-
fully treated with anti-asthmatic controller therapy includ-
ing ICS, a significant proportion of patients remain
uncontrolled.5
To our knowledge, this is the first controlled trial to show
that adult patients with HDM allergy–related asthma who
were not well controlled taking ICS can achieve an improve-
ment in asthma control as measured by time to first asthma
exacerbation with a sublingual tablet formulation of HDM
allergen immunotherapy. The trial showed an HR for the
FAS-MI of 0.69 [95% CI, 0.50-0.96] (absolute risk difference
for a moderate to severe asthma exacerbation: 0.10 [95% CI,
0.02-0.16]) in the 12 SQ-HDM group vs placebo group during
the ICS reduction period. For the 12 SQ-HDM group both the
FAS-MI and FAS results for the primary analysis met this pre-
specified effect size. Thus, the HDM SLIT tablet has been
shown to be effective in HDM allergy–related asthma both
among patients well controlled adhering to GINA treatment
steps 1 through 3,12,13 as well as among patients not well con-
trolled adhering to GINA treatment steps 2 through 4 at
inclusion. Together, the data confirm an effect on both cur-
rent asthma control and future risk.
Limitations of this trial include the operational definition
ofamoderateasthmaexacerbation that, toourknowledge,was
used for the first time.Althoughbeing applicable to a trial set-
ting, the establishment of a baseline and the twice daily diary
recordingswill have limitedusability in clinical practice. Also
the specific selection of patients within a set range of ICS use
and asthma control may pose a limitation. The trial had a
shorter duration than a standard course of immunotherapy
(often 3 years), which limits the conclusions on sustained ef-
fect. Furthermore, because the ultimate aim of allergen im-
munotherapy is disease-modification beyond the duration of
treatment, a follow-up after the end of treatmentwould have
been relevant.Additionally, the trialwasnotpowered for com-
parative assessment of adverse events.
Although all patients had a positive skin prick test result
for the HDM allergens, 66% of the participants had sensitiza-
tions to additional allergens included in the skin prick test
panel. There was no difference, however, in the response to
treatment with HDM SLIT tablet between patients sensitized
toHDMonly and patientswith additional sensitizations, sug-
gesting the HDM SLIT tablet was effective irrespective of pa-
tients being monosensitized or polysensitized.
The investigation of the effect on asthma exacerbations
during ICS reduction is a new patient-relevant primary end
point for allergen immunotherapy trials. Trials with asthma
controller medication evaluating exacerbations in asthma
have largely focused on severe exacerbations28,29; however,
the aim in this trial was deliberately to detect asthma exacer-
bations and intervene before they developed into severe
events. The concept of a moderate exacerbation has clinical
utility, as early recognition of exacerbations may prevent
patients from developing severe exacerbations, which ulti-
mately can be life-threatening. We found that the ATS/ERS
asthma exacerbation definition20 (moderate and severe
Table 3. Most Common Treatment-Related Adverse Events for Each Treatment Group Among ParticipantsWith HDM–Related Asthma
Placebo Group
(n = 277)
6 SQ-HDM Group
(n = 275)a
12 SQ-HDM Group
(n = 282)a,b
No. of Patients
With Events (%)
No. of
Events
No. of Patients
With Events (%)
No. of
Events
No. of Patients
With Events (%)
No. of
Events
All treatment-related adverse events 48 (17) 69 107 (39) 247 130 (46) 351
Gastrointestinal disorders 0 0 0 0 0 0
Oral pruritus 8 (3) 8 37 (13) 45 55 (20) 78
Edema mouth 0 0 24 (9) 26 28 (10) 35
Tongue pruritus 1 (<1) 1 12 (4) 13 13 (5) 15
Oral paresthesia 0 0 15 (5) 20 12 (4) 15
Lip edema 0 0 3 (1) 3 9 (3) 10
Nausea 0 0 0 0 8 (3) 8
Lip pruritus 0 0 0 0 7 (2) 8
Lip swelling 0 0 4 (1) 4 6 (2) 7
Swollen tongue 0 0 1 (<1) 1 5 (2) 6
Respiratory, thoracic, and mediastinal
disorders
0 0 0 0 0 0
Throat irritation 4 (1) 4 21 (8) 26 27 (10) 32
Pharyngeal edema 0 0 0 0 5 (2) 6
Ear and labyrinth disorders 0 0 0 0 0
Ear pruritus 2 (<1) 2 7 (3) 7 11 (4) 11
Injury, poisoning, and procedural
complications
0 0 0 0 0 0
Accidental overdose 9 (3) 12 4 (1) 5 15 (5) 16
Abbreviation: HDM, house dust mite.
a The biological activity of the house dust mite sublingual allergen immunotherapy tablet is related to the activity of the allergens
and is expressed in the unit SQ-HDM.
bAdverse events occurred in less than 1% of the 12 SQ-HDM group.
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exacerbations) was a sensitive primary trial outcome in this
trial design. The measurement of time-to-first exacerbation
was also recommended by the ATS/ERS joint task force
report.20 Previous trials with HDM allergen immunotherapy
have focused on ICS reduction, asthma symptom scores, or
lung function as primary end points with varying
success.30-32 In this trial, the intervention was added to stan-
dard anti-inflammatory treatment of asthma. The fact that
the HDM SLIT tablet prevented asthma exacerbations when
ICS was reduced could indicate an anti-inflammatory action
of the active treatment that maintains the level of asthma
control even in the absence of ICS. Efficacy was assessed in
all asthma exacerbations in general as opposed to exacerba-
tions induced by HDM exposure specifically. Furthermore,
the treatment effect was evident in the primary end point
and in a number of key and exploratory secondary end
points, including immunological parameters.
The HDM SLIT tablet induced allergen-specific immuno-
logical changes typically associated with allergen immuno-
therapy (key secondary end point). This is supportive of the
current assumption that the therapeutic effect is related to
modulationof the immunological response to theallergen.33-35
The third and fourth key secondary end points, ACQ and
AQLQ(S) score adjusted for ICS use, were novel attempts to
makecompositeendpointsevaluatingsimultaneously theMID
change from baseline in ACQ and AQLQ(S) score and change
from baseline in ICS. It was found that 79% to 85% of partici-
pants improved in both the ACQ and AQLQ(S) scores with no
differencesbetweengroups, including theplacebogroup.Thus
the active treatment did not provide added benefit for these
composite end points with patient-centered outcomes. The
continuous improvement inACQandAQLQ(S) score adjusted
for ICS use over time was seen even following ICS with-
drawal, which was unexpected.
Severe and uncontrolled asthma has been known to con-
stitute a risk in allergen immunotherapy. Therefore, partici-
pants with an FEV1 lower than 70% of predicted value at ran-
domization and participants with an asthma exacerbation
leading tohospitalizationwithin the last 3monthsprior to ran-
domizationwereexcludedfromthetrial.During theentire trial,
theparticipant’s asthmastatuswascarefullymonitored.There
was a dose-dependent change in the numbers of participants
with treatment-relatedadverseevents; primarilymild tomod-
erate local reactions that lasted for some minutes after each
tablet intakefor the firstdays toweeks.Thesafety findings from
this trial are similar to previous trials with the HDM SLIT
tablet.12-15
Basedon a cost-minimization analysis using aDanish set-
ting as an example, the total treatment costs, including only
direct costs, of a 3-year treatmentwith theHDMSLIT tablet is
€3089 (approximately US $3400).36
Conclusions
AmongadultswithHDMallergy–related asthmanotwell con-
trolledby ICS, theadditionofHDMSLIT tomaintenancemedi-
cations improved time to first moderate or severe asthma ex-
acerbation during ICS reduction, with estimated absolute
reduction at 6months of 9 to 10percentagepoints; the reduc-
tion was primarily due to an effect on moderate exacerba-
tions.Treatment-relatedadverseeventswere commonatboth
active doses. Further studies are needed to assess long-term
efficacy and safety.
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